Navigation Links
Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007 /PRNewswire-FirstCall/ -- Data analyses from the largest initial registration clinical trial program ever undertaken in the renal anemia arena provide efficacy and safety information on the investigational anemia therapy MIRCERA(TM) for the treatment of renal anemia associated with chronic kidney disease (CKD) in patients on dialysis and not on dialysis. Three data analyses were presented at the National Kidney Foundation 2007 Spring Clinical Meetings in Orlando, Florida.

According to these analyses, MIRCERA with extended dosing up to once every four weeks: (1) corrected and maintained hemoglobin (Hb) levels in patients with CKD, on dialysis and not on dialysis; (2) maintained Hb levels in dialysis patients, regardless of congestive heart failure (CHF) status as shown in a post-hoc analysis; and (3) exhibited a safety profile that is consistent with that of commercially available erythropoiesis stimulating agents (ESAs) and typical of those associated with this patient population.

"The goal in treating renal anemia is to safely maintain target hemoglobin levels," said Steven Fishbane, MD, Associate Director of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease research at Winthrop University Hospital. "These data analyses clearly demonstrate that MIRCERA corrected low hemoglobin levels, and maintained target hemoglobin levels with the added convenience of up to once- monthly dosing."

About the Studies

Safety and Tolerability of C.E.R.A. In Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials

Pooled data from four Phase II and six Phase III studies evaluated the safety and tolerability of MIRCERA (intravenous (IV) and subcutaneous (SC)) in patients not previously treated with commercially available ESAs and those previously treated with commercially availa
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
5. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
6. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:5/7/2008)... -- Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) a....,initiated a Phase 1 clinical trial of a drug can... to develop compounds to treat psychiatric disorde...tended for the treatment of a,common psychiatric d...ding partner, Taisho,effectively continue its eff...
(Date:5/7/2008)...ied in the inner ear, a finding,that could explain... or,overdose of drugs, MEMPHIS, Tenn., May 7 /P...rch Hospital investigators have found that an elec...chlea of the ear is critical to the acute,hearing ...ble better,understanding of how hearing loss can r...
(Date:5/7/2008)...atric Association Annual Meeting, WASHINGTON, May...Inc.,(NYSE: FRX ) announced today that study resu...tly improved symptoms of depression as compared to...scents, aged 12-17, with,major depressive disorder...he 2008 Annual Meeting of the American Psychiatric...
(Date:5/7/2008)...ta to be held Tuesday, May 13th, MENLO PARK, Cali...asdaq: XTNT ) today announced that six-month foll...nted at EuroPCR, taking place May 13 to 16 in,Barc...nce call to review,the new CUSTOM III data immedia...ion, two-year CUSTOM I data, previously presented ...
Breaking Medicine Technology:Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 2St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 2Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 5Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 6XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 2XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 3XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 4Getting Beach Ready Calls for More Than Hitting the Gym 16982 1Getting Beach Ready Calls for More Than Hitting the Gym 16982 2Lilly to Streamline Indianapolis Manufacturing and Engineering Operations 16979 1Lilly to Streamline Indianapolis Manufacturing and Engineering Operations 16979 2Lilly to Streamline Indianapolis Manufacturing and Engineering Operations 16979 3MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 4647 1MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 4647 2Free Prostate Cancer Seminar in Lake Ridge VA 3A Dr Charles Snuffy Myers Announces Vitamin D Clinical Trials 1825 1Free Prostate Cancer Seminar in Lake Ridge VA 3A Dr Charles Snuffy Myers Announces Vitamin D Clinical Trials 1825 2
...oth Efficacy and Safety, LEXINGTON, Mass., June 07...ticals, Inc. today announced final results from,it...osterone,undecanoate), a long- acting injectable t...tment of male hypogonadism which the,Company licen...ta,from the recently completed 48-week trial showe...
...Newswire-FirstCall/ -,Neurochem (International) Li...urochem Inc. , announces that the New England,Jour...e "Eprodisate,For AA Amyloidosis Trial" (EFAAT), r...ch for a treatment of AA amyloidosis. The,results ...(KIACTA(TM)) demonstrate that this product candida...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5
(Date:5/10/2008)...art to avoid devastating vision injuries, group sa... -- Every year in the United States, about 40,000 ...e American Academy of Ophthalmology (AAO), which r...ts-specific eye protection properly fitted by an e...rbonate materials offer the highest level of impac...
(Date:5/9/2008)...RNewswire-FirstCall/ -- Cynosure, Inc.,(Nasdaq: C...road array of,light-based aesthetic treatment syst...pproval from the Korea Food & Drug Administration ...or the removal of pigmented,lesions., Introduced ...third,Cynosure flagship product approved for marke...
(Date:5/9/2008)...ated for Maintenance Treatment for ADHD, INDIANAP...d Company,(NYSE: LLY ) announced today that the U...s approved Strattera(R) (atomoxetine HCI) for,main...ty Disorder (ADHD) in,children and adolescents. St...itor, is the first FDA-approved non-stimulant to t...
(Date:5/9/2008).../PRNewswire-USNewswire/ -- International,Rescue Co...nmar and four,additional teams are on standby for ... possible outbreak of water-borne diseases in cycl...estroyed in the villages I assessed today and,the ...ng water," says the,IRC,s emergency coordinator, G...
Breaking Medicine News(10 mins):Health News:Protective Eyewear Key to Sports Safety 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2
...f tomato-based foods such as pizza or tomato sauce...h as 30 percent, according to a new Harvard study....hor Howard Sesso, an assistant professor at the Ha...en's Hospital in Boston. "They're encouraging enou...
...nd regularly through activities such as reading, d...risk losing some of your cognitive abilities as yo...ng in the June 19 issue of the New England Journal...nstein College of Medicine in New York City found ...
...risks among homeless people are dramatically diffe...hers in Denmark followed more than 750 homeless pe...two groups: a registration group and an interview ... provided in annual reports for the registration g...
...ontraceptives are safe for non-smokers but can be ...rs ago and included 17,000 women. Oral contracepti... has long been a question of whether being on the ... chance for cancer or other fatal diseases. As par...
Other Medicine News:
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: